NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Xechem International, Inc. (OTC BB: XKEM) announced today the recent addition of Dr. Robert Swift as the new member of the Board of Directors of Xechem International, Inc. Dr. Swift received his Ph.D. in Biochemistry from Michigan State University and his M.B.A. in Finance from Indiana University. He has 15 years of experience in molecular biology, cancer research, biopharmaceuticals, and medical devices, and over ten years of experience in drug research and pre-clinical development with Eli Lilly and Company. He worked as a biotechnology analyst and an investment banker for five years, and was the Director of Research in Life Sciences at C.E. Unterberg, Towbin. In 2001, he joined Origin Capital Management and was co-portfolio manager until 2004. Presently he serves as a healthcare consultant.
